Abstract
Abstract
Background
A Japanese cohort study previously reported that not attending health checkups was associated with an increased risk of treated end-stage kidney disease (ESKD). The present study aimed to examine this association at the prefecture level.
Methods
We conducted an ecological study of all prefectures in Japan (n = 47) using five sources of nationwide open data. We explored associations of participation rates for Specific Health Checkups (SHC participation rates), the estimated prevalence of chronic kidney disease (CKD), and the ratio of nephrology specialists for each prefecture with prefecture-specific standardized incidence rates (SIRs) of treated ESKD using structural equation modeling.
Results
Prefecture-specific SHC participation rates ranged from 44.2% to 65.9%, and were negatively correlated with prefecture-specific SIRs and prevalence of CKD, and positively correlated with the ratio of nephrology specialists. SHC participation rates had significant negative effects on prefecture-specific SIRs (standardized estimate (β) = − 0.38, p = 0.01) and prefecture-specific prevalence of CKD (β = − 0.32, p = 0.02). Through SHC participation rates, the ratio of nephrology specialists had a significant indirect negative effect on prefecture-specific SIRs (β= − 0.14, p = 0.02). The model fitted the data well and explained 14% of the variance in SIRs.
Conclusions
Our findings support the importance of increasing SHC participation rates at the population level and may encourage people to undergo health checkups.
Funder
Ministry of Health, Labour and Welfare
Publisher
Springer Science and Business Media LLC
Subject
Physiology (medical),Nephrology,Physiology
Reference25 articles.
1. United States Renal Data System. 2022 USRDS Annual Data Report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2022.
2. Usami T, Koyama K, Takeuchi O, Morozumi K, Kimura G. Regional variations in the incidence of end-stage renal failure in Japan. JAMA. 2000;284(20):2622–4. https://doi.org/10.1001/jama.284.20.2622.
3. Usami T, Nakao N, Fukuda M, Takeuchi O, Kamiya Y, Yoshida A, et al. Maps of end-stage renal disease and amounts of angiotensin-converting enzyme inhibitors prescribed in Japan. Kidney Int. 2003;64(4):1445–9. https://doi.org/10.1046/j.1523-1755.2003.00221.x.
4. Usami T, Nakao N, Fukuda M, Yoshida A, Kimura G. Renoprotective action of statin estimated from mapping renal failure in Japan. Kidney Int. 2004;65(4):1520. https://doi.org/10.1111/j.1523-1755.2004.555_3.x.
5. Kato N, Usami T, Fukuda M, Motokawa M, Kamiya Y, Yoshida A, et al. Different regional dynamics of end-stage renal disease in Japan by different causes. Nephrology (Carlton). 2005;10(4):400–4. https://doi.org/10.1111/j.1440-1797.2005.00404.x.